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Genetic variation in the renin–angiotensin–aldosterone system
is associated with cardiovascular risk factors and early mortality
in established coronary heart disease
KL Ellis1, BR Palmer1, CM Frampton1, RW Troughton1, RN Doughty2, GA Whalley2,3, CJ Ellis2, AP Pilbrow1, L Skelton1,
TG Yandle1, AM Richards1 and VA Cameron1
This study examined renin–angiotensin–aldosterone (RAAS) system gene variants for associations with cardiovascular risk factors
and outcomes in coronary heart disease. Coronary disease patients (n¼ 1186) were genotyped for 21 single-nucleotide
polymorphisms (SNPs) within angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin-II type-1 receptor (AGTR1)
and aldosterone synthase (CYP11B2). Associations with all-cause mortality and cardiovascular readmissions were assessed over a
median of 3.0 years. The AGT M235T ‘T’ allele was associated with a younger age of clinical coronary disease onset (P¼ 0.006), and
the AGT rs2478545 minor allele was associated with lower circulating natriuretic peptides (P¼ 0.0001–P¼ 0.001) and E/E1
(P¼ 0.018). Minor alleles of AGT SNPs rs1926723 and rs11122576 were associated with more frequent history of renal disease
(Pp0.04) and type-2 diabetes (Pp0.02), higher body mass index (Pp0.02) and greater mortality (Pp0.007). AGT rs11568054 minor
allele carriers had more frequent history of renal disease (P¼ 0.04) and higher plasma creatinine (P¼ 0.033). AGT rs6687360 minor
allele carriers exhibited worse survival (P¼ 0.02). ACE rs4267385 was associated with older clinical coronary disease onset
(P¼ 0.008) and hypertension (P¼ 0.013) onset, increased plasma creatinine (P¼ 0.01), yet greater mortality (P¼ 0.044). Less history
of hypertension was observed with the AGTR1 rs12685977 minor allele (P¼ 0.039). Genetic variation within the RAAS was
associated with cardiovascular risk factors and accordingly poorer survival.
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INTRODUCTION
Global trends predict a steady rise in cardiovascular disease in the
next decade, and by 2020 coronary heart disease is predicted to
be the leading cause of death worldwide.1 Although lifestyle is
established as having an important role,2 the influence of genetics
on susceptibility to coronary heart disease has been demonstrated
in many large candidate gene3 investigations and more recently
genome-wide association studies.4 Cardiovascular disease likely
arises as a result of complex interactions between multiple genetic
and environmental factors each conferring a small cumulative
increase in risk.
The renin–angiotensin–aldosterone (RAAS) system has a central
role in the regulation of renal sodium and water absorption, blood
pressure, the control of thirst, cardiac function and cellular
growth,5 and has been established as one of the most
important systems in the pathogenesis of coronary heart
disease. With cardiac injury and impaired cardiac output the
RAAS is inappropriately activated leading to vasoconstriction and
deleterious increases in peripheral vascular resistance, retention of
sodium and water and damaging hypertrophic and fibrotic effects
on the heart and vasculature. Drugs that target the RAAS cascade
currently constitute a central pillar of cardiovascular therapeutics.6
In the classical RAAS, circulating renin metabolizes angiotensi-
nogen (AGT), produced predominantly in the liver to form the
decapeptide angiotensin-I (Ang-I). Inactive Ang-I is hydrolyzed by
angiotensin-converting enzyme (ACE), removing the C-terminal
dipeptide and leaving the biologically active and potent
vascoconstrictor octapeptide Angiotensin-II (Ang-II (1–8)). Ang-II
is then further processed by aminopeptidase A and N to produce
angiotensin III and angiotensin IV.7 Ang-II interacts with both the
angiotensin-II type-1 and angiotensin-II type-2 G-protein-coupled
receptors.7
Ang-II also acts at the adrenal zona glomerulosa to trigger the
secretion of aldosterone. In heart failure Ang-II becomes the major
aldosterone secretagogue as opposed to potassium and cortico-
tropin in normal health.8 Aldosterone is an independent risk factor
for cardiovascular disease and stimulates both renal and
extrarenal retention of sodium and water9 and cardiac collagen
synthesis and fibroblast proliferation via the activation of local
mineralocorticoid receptors10 leading to adverse remodeling.
In severe heart failure, the pharmacological blockade of
these receptors with mineralocorticoid antagonists such as
spironolactone and eplerenone, has been shown to significantly
reduce both morbidity and mortality in these patients.11
Numerous RAAS gene linkage and gene association studies have
reported associations with cardiovascular diseases, including hyper-
tension.12 Within the AGT gene, the coding M235T and T174M
polymorphisms have been particularly well studied, as have the
ACE insertion/deletion and angiotensin-II type-1 receptor (AGTR1)
A1166C gene variants.12 Any pathophysiological association
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between these polymorphisms and CAD is plausibly via an increase
in RAAS activity.
Whether genetic variation within this system has a role in
disease progression is unknown. We have screened polymorph-
isms in genes encoding AGT, ACE, AGTR1 and CYP11B2, selected
either because of previous associations with CAD risk or as key
tagging single-nucleotide polymorphisms (SNPs) in these genes,
for association with cardiovascular risk factors and outcomes in a
prospective cohort of patients with established coronary heart
disease.
METHODS
Coronary disease cohort
Patients (n¼ 1186) were recruited into the study according to the
following inclusion criteria; ischemic discomfort plus one or more of
electrocardiogram changes (ST segment depression or elevation of at least
0.5mm, T-wave inversion of at least 3mm in at least three leads, or left
bundle branch block), elevated levels of cardiac markers, a history of
coronary disease, or were aged at least 65 years in patients with diabetes
or vascular disease. Patients were excluded from the study if they had a
severe comorbidity that limited their life expectancy to less than 3 years.
Plasma was collected at a baseline clinic, 5–56 days from the date of index
admission. Blood was collected into chilled EDTA tubes and stored on ice.
Plasma was separated within 20min by centrifugation and stored at
 80 1C. Plasma was assayed for atrial natriuretic peptide (ANP),13
N-terminal ANP (NT-proANP),14 B-type natriuretic peptide (BNP),15
N-terminal B-type natriuretic peptide (NT-proBNP),16 C-type natriuretic
pepetide (CNP)17 and cyclic guanosine monophosphate (cGMP).18
Transthoracic echocardiography was performed using a GE Vivid 3
ultrasound system (GE Medical Systems, Waukesha, WI, USA) at
Christchurch Hospital and an ATL HDI 5000 (Philips Healthcare, Andover,
MA, USA) at Auckland City Hospital. The standardized imaging protocol
included apical 4- and 2-chamber views according to the American Society
of Echocardiography.19
Patients were followed for a median 3.0 years (0.1–3.0 years). Diagnoses
at each readmission were defined using the International Statistical
Classification of Diseases and Health Related Problems 10th Revision (ICD-
10). Outcome data were obtained from National Health Information
Systems and hospital Patient Management Systems databases and
cardiovascular admissions were determined at discharge by clinical review.
The study conformed to the principles outlined in the Declaration of
Helsinki and Title 45, US Code of Federal Regulations, Part 46 and was
approved by the New Zealand Multi-region Ethics Committee (Reference
No. CTY/02/02/018). Each participating patient provided written, informed
consent.
DNA extraction and genotyping
Extraction of genomic DNA was performed as described previously.20 For
AGT, patients were screened for M235T (rs699), T174M (rs4762) and six tag
SNPs (rs2478539, rs6687360, rs11568054, rs11122576, rs1926723 and
rs2478545). The ACE intron 16 I/D (rs4646994) and three ACE tag SNPs
(rs4329, rs4353 and rs4267385) were assayed, as was the AGTR1 A1166C
polymorphism and seven AGTR1 tag SNPs (rs2933249, rs931490,
rs1492103, rs718858, rs1492103, rs718858, rs1492099, rs12721331 and
rs12695877). Study participants were additionally genotyped for the
CYP11B2 C-344T polymorphism. For each gene, tag SNPs were selected
from HapMap data for the CEU population (Utah residents with ancestry
from northern and western Europe) (Supplementary Figures 1–3).
The ACE intron 16 I/D (rs4646994) assay was performed as previously
described.20 ACE rs4267385 was genotyped using a PCR-RFLP assay
consisting of the amplification primers: forward 50-CCT TGT GTG CCC TCT
CCT AA-30 and reverse 50-ATG GAT GGA TGG ATG GAT GT-30 . PCR
amplification included an initial denaturation of 4min at 94 1C, 30 cycles
of 60 sec denaturation at 94 1C, 1min annealing at 60 1C and 1min
extension at 72 1C and final extension of 7min at 72 1C. The resulting
219 bp amplimer was digested with NspI (New England Biolabs,
Beverly, MA, USA) and visualized on large format 2% agarose,
0.5 TBE gel with ethidium bromide staining. The T allele yielded
digestion products of 42 and 177 bp. All other genotyping was
performed using 100 ng of DNA and either SNPlex (Applied
Biosystems, Mulgrave, Victoria, Australia) or TaqMan genotyping assays
(Applied Biosystems) according to the manufacturers instructions.
Statistical analyses
Associations between genotype and baseline patient characteristics were
tested using an additive genetic model, except for those SNPs where the
minor genotype occurred at a frequency of o10%. For these variants a
dominant genetic model was used. Hormone data exhibited a skewed
distribution and was log transformed. Before undertaking statistical
analyses to investigate the association between SNPs and baseline
characteristics, associations between genotype and ethnicity were
assessed. For SNPs where a significant difference in genotype frequency
was observed, subsequent analyses were performed on each ethnic
subgroup separately as well as on the cohort as a whole. Ethnicity, as well
as other factors (including age, gender and body mass index (BMI)) were
adjusted for in univariate analyses where there is evidence to suggest that
these could be potential confounding factors. Ethnicity was self-declared
and was based on grandparent information. Patients were predominantly
of European ancestry (83.3%). The majority of study participants of Other
ethnicity were of Maori/Pacific Island, Asian and Unknown ancestry. For
continuous variables, associations with baseline patient characteristics
were assessed using ANOVA with a linear contrast, with the results
summarized as the regression coefficient (b) and 95% confidence intervals.
Odds ratios and 95% confidence intervals are reported for discrete
variables. The primary endpoint was death; however, secondary associa-
tions between genotype and readmission for non ST-elevation MI (the
most common cause of cardiovascular disease readmission) were explored.
Univariate associations between each variant and outcome was assessed
using Kaplan–Meier survival analyses and the log-rank test statistic of
linear trend. Cox-proportional hazard analysis was performed to establish
independent associations with outcome by adjusting for established
predictors of increased risk; age of disease onset, gender, ethnicity, history
of myocardial infarction, history of hypertension, b-blocker treatment,
plasma creatinine, left ventricular ejection fraction and NT-proBNP.
Cox-proportional hazards modeling was performed if the association
between SNP and outcome was Po0.1 in Kaplan–Meier analyses. The
power of this study to assess the relationship between genotype and
cardiovascular outcomes was estimated assuming 80% power and two-
tailed a¼ 0.05. Adopting a conservative approach, this resulted in power to
detect a hazard ratio of p1.79. Analyses were performed using PASW
version 18.0 (SPSS Inc. Chicago, IL, USA).
RESULTS
Coronary disease cohort patient characteristics
Patient characteristics of the Coronary Disease Cohort Study are
shown in Table 1. Genotype frequencies of each RAAS poly-
morphism are shown in Table 2. Throughout 3-year follow-up,
cumulative mortality was 12.5% (n¼ 147) and 20.3% (n¼ 239) of
patients were readmitted for non ST-elevation MI.
AGT polymorphisms
AGT rs2478545 minor allele carriers (n¼ 373) had lower levels of
circulating ANP (P¼ 0.00017; b¼  1.16; 95% CI¼  1.25 to
 1.07), NT-proANP (P¼ 0.00012; b¼  1.15; 95% CI¼  1.23 to
 1.07), BNP (P¼ 0.00025; b¼  1.23; 95% CI¼  1.37 to  1.10),
NT-proBNP (P¼ 0.00049; b¼  1.24; 95% CI¼  1.39 to  1.10),
CNP (P¼ 0.001; b¼  1.10; 95% CI¼  1.17 to  1.04) and cGMP
(P¼ 0.013; b¼  1.09; 95% CI¼  1.16 to  1.02) after adjust-
ment for potential confounders age, gender, ethnicity and BMI.
The minor allele of rs2478545 was associated with a lower
adjusted E/E1 (P¼ 0.018; b¼  1.01; 95% CI¼  1.84 to  0.18).
Minor alleles of rs1926723 and rs11122576 were associated with
a greater prevalence of type-2 diabetes (rs1926723, P¼ 0.020,
OR¼ 1.59, 95% CI¼ 1.07 to 2.35; rs11122576, P¼ 0.018, OR¼ 1.60,
95% CI¼ 1.09 to 2.37) and a larger BMI (rs1926723, P¼ 0.008,
b¼ 1.07, 95% CI¼ 0.28 to 1.86; rs11122576, P¼ 0.021, b¼ 0.93,
95% CI¼ 0.14 to 1.73) (Table 3). The same genotypes were also
associated with a more frequent history of renal disease
(rs1926723, P¼ 0.042, OR¼ 1.63; 95% CI¼ 1.02 to 2.62;
rs11122576, P¼ 0.023; OR¼ 1.72; 95% CI¼ 1.08 to 2.75). To
confirm that this association did not result from overrepresenta-
tion of the minor allele among at-risk ethnic groups, the major
ethnic subgroups were analyzed separately. For both SNPs, trends
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in the same direction were observed with renal disease and type-2
diabetes in both the European (P¼ 0.151–0.227) and combined
other/unknown (P¼ 0.073–0.121) patient groups. Patients carrying
the ‘T’ allele of rs11568054 demonstrated a more frequent history
of renal disease (P¼ 0.04; OR¼ 1.82; 95% CI¼ 1.03 to 3.21) and
higher levels of plasma creatinine (P¼ 0.033; b¼ 1.08; 95%
CI¼ 1.01 to 1.16).
The AGT 235 ‘TT’ ‘high-risk’ genotype was associated with a 2.9-
year younger age of clinical coronary disease onset (P¼ 0.006;
b¼  1.41; 95% CI¼  2.42 to  0.41) (Table 3). As the minor
allele of M235T, was less frequent in patients of European ancestry
when compared with those of other/unknown ethnicity, the
analyses for these SNPs were run on both patient groups
separately. The association between the 235 ‘T’ allele and a
younger age of clinical coronary disease onset was present in the
other/unknown ethnic groups only (Po0.043).
Kaplan–Meier survival analysis revealed that in addition to a
higher BMI, and more type-2 diabetes and renal disease, AGT
rs11122576 (log-rank P¼ 0.045) and rs1926723 (log-rank
P¼ 0.049) minor allele carriers experienced greater mortality
(Figure 1). The AGT rs6687360 minor allele trended towards worse
survival (log-rank P¼ 0.055, Figure 1). For each variant, the
association with increased mortality was significant when adjust-
ing for ethnicity and other established predictors of increased risk
(Pp0.020, Table 4).
ACE polymorphisms
The minor allele of ACE rs4267385 was associated with an older
age of onset of clinical coronary disease (P¼ 0.008; b¼ 1.58; 95%
CI¼ 0.43 to 2.72) and hypertension onset (P¼ 0.016; b¼ 2.15; 95%
CI¼ 041 to 3.88) and higher plasma creatinine (P¼ 0.01; b¼ 1.04;
95% CI¼ 1.01 to 1.07) (Table 3). Despite this, ACE rs4267385 was
additionally associated with increased mortality in both univariate
(log-rank P¼ 0.002, Figure 1) and multivariate (P¼ 0.044, Table 4)
survival analyses.
Patients carrying the ‘high-risk’ ACE I/D ‘D’ allele, were more
likely to be readmitted for non ST-elevation MI, the most common
cause of CVD readmission in the cohort overall (log-rank P¼ 0.038,
Figure 2). However, in multivariate analyses that adjusted for
established predictors of increased risk, ACE I/D genotype was not
independently prognostic (P¼ 0.131, Supplementary Table 1). No
differences in age, gender, ethnicity or pharmacotherapy were
observed with ACE genotype.
AGTR1 polymorphisms
Less frequent history of hypertension was observed for AGTR1
rs12695877 minor allele carriers (P¼ 0.039; OR¼ 0.82; 95%
CI¼ 0.68 to 0.99) (Table 3). Univariate outcome analyses identified
a significant association between AGTR1 rs2933249 (log-rank
P¼ 0.03), rs1492103 (log-rank P¼ 0.027) and readmission for non
ST-elevation MI (Figure 2). However, when adjusting for established
predictors of increased risk, no association between AGTR1
genotype and readmission for non ST-elevation MI was observed
(P¼ 0.083–0.087, Supplementary Table 1). There were no associa-
tions between AGTR1 genotype, gender or pharmacotherapy.
Minor alleles of rs2933249, rs931490, rs1492103 and rs1492099
occurred at a lower frequency in European patients when
compared with individuals of other/unknown ethnicity (Po0.05;
European minor allele frequency¼ 0.176–0.241, other/unknown
minor allele frequency¼ 0.268–0.328). AGTR1 SNP rs718858
occurred at an increased frequency in participants of European
descent (P¼ 0.030; European minor allele frequency¼ 0.376, other/
unknown minor allele frequency¼ 0.307).
Aldosterone synthase CYP11B2 C-344T
Genotype frequencies for CYP11B2 C-344T were as follows,
CC¼ 31.0% (n¼ 354), CT¼ 48.6% (n¼ 555) and TT¼ 20.4%
(n¼ 233). There were no associations between CYP11B2 C-344T
and baseline patient characteristics or cardiovascular outcomes,
Table 1. CDCS baseline patient characteristics
n
Age (years)a 1180 66.9±12.5
Gender (M) 1182 70.6%
Ethnicity 1168
European 973 83.3%
Other/unknown ethnicity 195 16.7%
BMI (kgm 2)a 1159 27.4±4.8
Current smoker 1173 7.2%
Hypertension 1169 53.4%
Previous MI 1167 31.6%
Type-2 diabetes 1174 16.4%
Family history of CAD 1153 46.7%
b-Blocker-treated 1176 86.5%
ACE inhibitor-treated 1176 57.1%
Plasma NT-pro BNP (pmol l 1)b 1165 77.6(0.93–2187.8)
Left ventricular ejection fractiona 1054 56.8±12.8
Plasma creatinine (mmol l 1)b 1161 0.1(0.02–0.95)
Diagnosis at discharge 1162
Non ST-elevation MI 583 50.2%
ST-elevation MI 236 20.3%
Unstable angina 343 29.5%
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass
index; MI, myocardial infraction; CAD, coronary artery disease; NT-pro
BNP, N-terminal brain natriuretic peptide. aArithmetic mean±s.d. bGeo-
metric mean and range.
Table 2. Genotype frequencies of RAAS polymorphisms in the CDCS
cohort
n AA, n (%) Aa, n (%) aa, n (%)
AGT
rs1926723 (A/G) 987 801 (81.2) 163 (16.5) 23 (2.3)
rs2478545 (C/T) 991 618 (62.4) 331 (33.4) 42 (4.2)
rs2478539 (A/C) 812 349 (43.0) 328 (40.4) 135 (16.6)
rs6687360 (C/T) 938 383 (40.8) 422 (45.0) 133 (14.2)
rs11568054 (C/T) 943 833 (88.3) 104 (11.0) 6 (0.6)
rs11122576 (A/G) 994 808 (81.3) 173 (17.4) 13 (1.3)
rs699 (M235T) 1164 399 (34.3) 541 (46.5) 224 (19.2)
rs4762 (T174M) 1165 906 (77.8) 248 (21.3) 11 (0.9)
ACE
rs4646994
(ACE I/D)
936 207 (22.1) 424 (45.3) 305 (32.6)
rs4267385 (C/T) 914 194 (21.2) 463 (50.7) 257 (28.1)
rs4329 (A/G) 927 277 (29.9) 454 (49.0) 196 (21.1)
rs4353 (A/G) 929 261 (28.1) 460 (49.5) 208 (22.4)
AGTR1
rs2933249 (C/T) 986 679 (68.9) 279 (28.3) 28 (2.8)
rs12695877 (T/C) 991 427 (43.1) 446 (45.0) 118 (11.9)
rs931490 (A/G) 941 653 (69.4) 261 (27.7) 27 (2.9)
rs1492103 (T/C) 903 637 (70.5) 244 (27.0) 22 (2.4)
rs718858 (C/T) 988 670 (67.8) 289 (29.3) 29 (2.9)
rs1492099 (G/A) 986 739 (74.9) 228 (23.1) 19 (1.9)
rs12721331 (T/C) 900 785 (87.2) 110 (12.2) 5 (0.6)
rs5186 (A1166C) 1185 628 (53.0) 458 (38.6) 99 (8.4)
CYP11B2
rs1799998
(C-344T)
1142 354 (31.0) 555 (48.6) 233 (20.4)
Where ‘A’ represents the major allele and ‘a’ the minor allele for each SNP.
SNPs italicized and in bold were selected based on previous associations
reported in the literature. All other SNPs are ‘tag’ SNPs and were identified
from HapMap data for the CEU population.
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and no difference in genotype frequency with gender, ethnicity,
comorbidity or pharmacotherapy.
DISCUSSION
Inappropriate RAAS activation is a major pathophysiological
culprit in cardiovascular disease. To our knowledge we have for
the first time reported a broad screen of RAAS polymorphisms in a
prospective study of patients with established coronary heart
disease. Our data suggest a novel association between a genetic
variant in AGT (rs2478545) and significantly lower levels of
circulating natriuretic peptides. Two other AGT SNPs (rs1926723
and rs11122576) were consistently associated with a larger BMI,
type-2 diabetes, renal disease and accordingly poorer survival.
Variants within ACE and AGTR1 may be weakly associated with
increased mortality and/or history of hypertension.
The AGT gene is located on chromosome 1 at position 1q42,
spans over 11 kb, and contains five exons and over 215 known
polymorphisms. Among these, the M235T and T174M polymorph-
isms have been particularly well studied. Several meta-analyses
have reported small positive associations between both the 235T
and T174 alleles and hypertension,12 with blood pressure and
arterial stiffness,21 and with increased heart failure mortality.22 AGT
235 ‘TT’ homozygotes have also been shown to have
approximately 20% higher concentrations of plasma AGT.23
Consistent with these findings, in the current study, participants
with the AGT 235 ‘TT’ genotype were younger at the time of
recruitment by 2.9 years. Although it has been demonstrated that
M235T is non-functional, this variant is in tight linkage
disequilibrium with a variant in the proximal promoter of the
AGT gene.24 This variant encodes an adenine instead of a guanine
six nucleotides upstream from the site of transcription (-6A/G), and
has been shown to affect the interaction between at least one
trans-acting nuclear factor and the promoter of the AGT gene.23
This is likely to explain the increased levels of plasma AGT levels in
T235 homozygotes compared with M235 homozygotes.
In the current study, an intriguing association was observed
between the minor allele of the AGT tag SNP rs2478545 and
circulating levels of natriuretic peptides. The mutually antagonistic
actions of the natriuretic peptide system and the RAAS have been
well established. Cardiac natriuretic peptides directly reduce both
renin and aldosterone secretion, and their beneficial effects on the
cardiovascular system depend on their ability in part to
antagonize the RAAS at multiple levels.25 Interestingly, in this
Table 3. Significant associations between polymorphisms and CDCS baseline patient characteristics
AGT ANP (pmol l 1) NT-proANP
(nmol l 1)
BNP (pmol l 1) NT-proBNP
(pmol l 1)
CNP
(pmol l 1)
cGMP
(pmol l 1)
E/E1
rs2478545
CC 38.7 (36.7–40.7)* 1.1 (1.1–1.2)* 20.3 (18.8–21.8)* 85.9
(79.1–93.2)*
1.2
(1.2–1.3)*
6.9
(6.6–7.2)***
12.7±7.6***
CT/TT 32.6 (30.4–34.8) 1.0 (0.9–1.0) 15.8 (14.4–17.4) 65.4
(58.5–73.2)
1.1
(1.1–1.2)
6.3
(6.0–6.7)
11.4±4.9
History of renal disease Type-2 diabetes BMI (kgm 2)
rs1926723
AA 9.7%*** 16.1%*** 27.3±4.8**
AG/GG 14.9% 23.4% 28.3±5.4
rs11122576
AA 9.6%*** 16.0%*** 27.3±4.8***
AG/GG 15.5% 23.4% 28.2±5.4
History of renal disease Creatinine (mmol/l)
rs11568054
CC 9.2%*** 0.09(0.09–0.10)***
CT/TT 15.6% 0.10(0.09–0.10)
Age of coronary disease
onset (years)
M235T
MM 68.2±12.0
MT 67.1±12.8**
TT 65.3±12.7
ACE Age of coronary disease
onset (years)
Age of
hypertension
(years)
Creatinine
(mmol/l)
rs4267385
CC 66.9±12.0 49.4±14.9 0.09(0.09–0.10)
CT 67.5±12.9** 53.3±13.5*** 0.10(0.09–0.10)**
TT 69.9±11.5 53.9±12.5 0.10(0.09–0.11)
AGTR1 History of hypertension
rs12695877
CC 58.5%
CT 50.6%***
TT 51.3%
Abbreviations: ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic pepetide; cGMP, cyclic guanosine monophosphate;
NT-proANP, N-terminal ANP. Data are presented as arithmetic mean±s.d., geometric mean (95% CI), or as percentages unless otherwise indicated. Significance
*Po0.001,**Po0.01,***Po0.05.
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Figure 1. Association between AGT rs11122576, AGT rs1926723, AGT rs6687360 and ACE rs4267385 and mortality.
Table 4. Cox-proportional analysis of factors predictive of death and AGT rs11122576, rs1926723 and rs6687360 genotype
Variable AGT rs11122576 AGT rs1926723 AGT rs6687360 ACE rs4267385
Risk
ratio
95% CI P Risk
ratio
95% CI P Risk
ratio
95% CI P Risk
ratio
95% CI P
Age 1.06 1.03–1.08 o0.001* 1.06 1.03–1.08 o0.001* 1.05 1.02–1.08 o0.001* 1.06 1.03–1.09 o0.001*
Gender 0.82 0.50–1.37 0.452 0.80 0.49–1.33 0.397 0.73 0.43–1.22 0.227 1.27 0.79–2.06 0.323
Ethnicity — — 0.036* — — 0.038* — — 0.139 — — 0.467
Maori/Pacific
vs European
2.10 1.02–4.32 2.07 1.00–4.27 1.72 0.81–3.65 1.16 0.36–3.75
Asian vs
European
2.12 0.67–7.19 2.19 0.67–7.20 1.90 0.57–6.34 4.59 0.56–37.9
Other/
unknown vs
European
0.38 0.11–1.28 0.38 0.11–1.27 0.42 0.13–1.42 0.74 0.29–1.88
History of
myocardial
infarction
1.65 1.05–2.61 0.031* 1.63 1.03–2.57 0.036* 1.59 0.99–2.57 0.057 1.67 1.07–2.62 0.025*
History of
hypertension
1.22 0.76–1.96 0.406 1.22 0.76–1.95 0.412 1.15 0.70–1.90 0.585 0.83 0.53–1.29 0.406
B-blocker
treatment
0.88 0.45–1.70 0.692 0.87 0.45–1.69 0.680 1.19 0.62–2.27 0.607 0.50 0.30–0.84 0.009*
Creatinine
(mmol l 1)
3.53 1.59–7.85 0.002* 3.56 1.60–7.92 0.002* 3.87 1.68–8.93 0.001* 2.29 0.88–5.96 0.090
LVEF 0.98 0.97–1.00 0.044* 0.98 0.96–1.00 0.039* 0.98 0.96–1.00 0.038* 1.00 0.98–1.02 0.924
NT-proBNP
(pmol l 1)
4.14 2.00–8.58 o0.001* 4.01 1.93–8.31 o0.001* 5.28 2.47–11.28 o0.001* 6.37 2.93–13.82 o0.001*
Genotype 2.01 1.21–3.32 0.007* 2.05 1.24–3.39 0.005* 1.48 1.07–2.05 0.020* 1.37 1.01–1.86 0.044*
Abbreviation: LVEF, left ventricular ejection fraction. *Significance Po0.05. Bold values indicated statistically significance values Po0.05.
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current study the association between rs2478545 and lower
natriuretic peptides also translated into a lower E/E1, indicating
less ventricular diastolic dysfunction. Whether this suggests that
the rs2478545 minor allele is associated with less cardiac stress via
a natriuretic peptide-independent mechanism, accompanied by
lower natriuretic peptide levels, or whether the level of natriuretic
peptides is inappropriately low for given cardiac damage, is
difficult to determine. However, if the lower natriuretic peptides
were providing less compensatory cardioprotection, then it might
be expected that an association with worse outcomes would also
have been observed.
In the present study, two AGT variants (rs1926723 and
rs11122576), were associated with increased BMI, type-2 diabetes
and renal disease. Links between the RAAS and both the initiation
and progression of these diseases has been demonstrated, and
clinical trials have demonstrated that RAAS inhibition reduces the
incidence of vascular complications in diabetes patients.26 Minor
alleles of both rs1926723 and rs11122576 were also associated
with greater mortality over 3-year follow-up. These associations
with cardiovascular outcomes occurred despite the wide use of
medications that interrupt the RAAS over follow-up, potentially
indicating incomplete inhibition of this system.
Within the ACE gene, the D allele of the common insertion/
deletion (I/D) polymorphism in intron 16 has been shown to
predict approximately half the interindividual variability in both
serum and tissue levels of ACE,27 and DD homozygotes have been
identified at higher frequencies in hypertensive men than their
mildly hypertensive or normotensive counterparts.28 The ACE D
allele has proven to be a consistent marker of initial risk20,29 and a
predictor of clinical outcome after MI in prospective studies of at-
risk groups.20 Supporting these findings, in the current study the
ACE D allele was associated with an increased risk of experiencing
a subsequent non ST-elevation MI. However, as statistical
significance was lost when adjusting for several established risk
factors any association is likely to be modest. Previous associations
of the ACE D allele with elevated levels of ACE in human plasma27
and myocardium30 provides a mechanistic basis for the
polymorphism’s relationship with heart disease, given the
central role of the RAAS in the regulation of blood pressure,
sodium balance and cardiac remodeling following heart injury.
However, as ACE I/D is located within intron 6 of the ACE gene, this
polymorphism is unlikely to directly effect ACE activity. Instead,
other alleles in LD located within or nearby the ACE gene are
thought to explain the observed associations between ACE and
cardiovascular disease. In this study, we also identified an
association between the minor allele of the tag SNP rs4267385
and a 3 year older age of onset of clinical coronary disease and
onset of hypertension, but also a greater mortality independent of
age and other prognostic markers. These apparently conflicting
findings require further validation.
Located on chromosome 3q21-25, AGTR1 is 455 kb in length.
Of the more than 278 polymorphisms identified, the 30UTR
A1166C variant has been the most widely investigated. The AGTR1
A1166C ‘C’ allele has been shown in case–control studies to occur
at greater frequency in hypertensive patients than in normoten-
sive subjects.31 Within the general population, both clinic systolic
and diastolic blood pressures were determined to be on average
11.3mmHg and 4.2mmHg lower in CC homozygotes when
compared with AC heterozygotes and AA homozygote; however,
ambulatory blood pressure was similar across genotypes.32 It has
been hypothesized that this gene variant can activate the RAAS as
it is located in a cis regulatory site, recognized by the specific
microRNA, miR155.33 Although strong associations have been
reported in the literature between the A1166C variant and CVD
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Figure 2. Association between ACE I/D, AGTR1 rs1492103 and AGTR1 rs2933249 and readmission for non ST-elevation MI.
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characteristics in multiple populations,34 we observed no
association with baseline patient characteristics or cardiovascular
outcomes in coronary disease cohort study participants. In
contrast, the AGTR1 tag SNP rs12695877 was associated with
less history of hypertension, and both rs111492103 and
rs2933249 minor allele carriers were less likely to have been
readmitted for a non ST-elevation MI during the follow-up period.
The CYP11B2 C-344T polymorphism located in the promoter
region of the aldosterone synthase gene involves a C/T substitu-
tion in a putative binding site for the steroidogenic transcription
factor SF-1.35 The CYP11B2 -344T allele has been associated in
some but not all studies with an increased risk of hypertension,36
coronary disease37 and poorer event-free survival in African-
Americans with heart failure.38 However, in the current study no
association between C-344T and either baseline patient
characteristics or cardiovascular outcomes were observed. This
lack of association could reflect the widespread use of beta-
blockers, ACE inhibitors and angiotensin-II receptor blockers in
these coronary disease patients.
We have performed a broad screen of genetic variation within
the RAAS hormone system for association with cardiovascular risk
factors and outcomes in patients with established coronary heart
disease. Associations were observed between the minor allele of
AGT rs2478545 and lower levels of plasma natriuretic peptides,
and between the AGT M235T ‘T’ allele and an earlier age of clinical
coronary disease onset. Patients carrying the minor alleles of AGT
rs1926723 and rs11122576 had more history of renal disease and
type-2 diabetes, and increased mortality throughout follow-up.
AGT rs6687360 and ACE rs4267385 were independently prognostic
of all-cause mortality, and AGTR1 rs12685977 minor allele carriers
had less frequent history of hypertension. These observed
associations with cardiovascular risk factors and outcomes provides
further evidence that genetic variation within this important
hormone cascade has an integral role in the development and
progression of cardiovascular disease.
What is known about this topic
 The RAAS has a central role in the regulation of renal sodium and water
absorption, blood pressure, the control of thirst, cardiac function and
cellular growth, and has been established as one of the most important
systems in the pathogenesis of coronary heart disease.
 Numerous RAAS gene linkage and gene association studies have
reported associations with cardiovascular diseases, including
hypertension.
What this study adds
 To our knowledge, we have the first time reported a broad screen of
RAAS polymorphisms in a prospective study of patients with
established coronary heart disease.
 We have identified a novel association between a genetic variant in
AGT (rs2478545) and significantly lower levels of circulating natriuretic
peptides.
 Two other AGT SNPs (rs1926723 and rs11122576) were consistently
associated with a larger BMI, type-2 diabetes, renal disease and
accordingly poorer survival.
 Variants within ACE and AGTR1 may be weakly associated with
increased mortality and/or history of hypertension.
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